LATS1 and non-small cell lung carcinoma: Oncogenic alterations of the Hippo pathway in NSCLC include neurofibromin 2 (NF2) mutation, NF2 fusion, LATS1/2 mutation, LATS1 fusion, YAP1/TAZ fusion, and YAP1/TAZ gene amplification [46–50].